Clinical trials: Renin Angiotensin Aldosterone System
Metabolic Syndrome
Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i
This study will measure the effect of the agent tadalafil on glucose and insulin homeostasis in people with metabolic syndrome in the presence and absence of an ACE inhibitor.
- Trial name
- NCT00750308
- Testing
- Ramipril, Tadalafil
- Volunteers
- 27 people
- Sponsor
- Vanderbilt University
COVID-19
Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19
Background. Angiotensing converting enzyme type 2 (ACE2), a key enzyme of the renin-angiotensin-aldosterone system (RAAS), is the receptor of SARS-CoV-2 for cell entry into lungs.
- Trial name
- COVHYP (NCT04374695)
- Volunteers
- 700 people
- Sponsor
- Versailles Hospital
Hyperaldosteronism
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism
The tissue kallikrein-kinin (KKS) and renin-angiotension-aldosterone system (RAAS) had been implicated in regulating blood pressure and electrolyte homeostasis.
- Trial name
- NCT00155064
- Testing
- captopril, Losartan (drug)
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Type 2 Diabetes, Microalbuminuria
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
Aim: To evaluate the renoprotective effect as reflected by short-term changes in albuminuria of ultra high doses of irbesartan in Type 2 diabetic patients with microalbuminuria Design: A double-masked randomized cross-over trial…
- Trial name
- NCT00320879
- Testing
- irbesartan
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Steno Diabetes Center Copenhagen
COVID-19, SARS-CoV2 Infection
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT05593770)
- Testing
- Fostamatinib
- Where
- 21 sites in Brazil, Germany and 3 more
- Volunteers
- 28 people
- Sponsor
- NEAT ID Foundation
Hypertension, Metabolic Syndrome
The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome
Study purpose: African Americans with hypertension and markers of metabolic syndrome (small elevations in blood glucose, triglycerides and or weight) are at a high risk of cardiovascular (heart and blood vessel) problems.
- Trial name
- SAAVE (NCT01432106)
- Testing
- Aliskerin/Valsartan and Rampiril
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Michigan
Septic Shock
Alterations of the Renin-angiotensin-aldosterone System in sEptic Shock
Septic shock is a common and life-threatening condition associated with an in-hospital mortality rate exceeding 40%. The symptomatic management of septic shock relies primarily on vasopressor therapy, particularly norepinephrine.
- Trial name
- ARES (NCT07721974)
- Testing
- Collection of fluid samples
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Kidney Diseases, Hyperkalemia
Potassium Correction for RAAS Optimization in Chronic Kidney Disease
The goal of this placebo-controlled, double-blinded cross-over trial is to test whether patiromer, compared with placebo, better enables up-titration of RAAS-blocker treatment in patients with chronic kidney disease stage 3b/4.
- Conditions
- Chronic Kidney Diseases, Hyperkalemia, Hypertension
- Trial name
- PROMISE (NCT06256991)
- Testing
- Patiromer 8400 MG [Veltassa]
- Where
- Netherlands
- Volunteers
- 44 people
- Sponsor
- University Medical Center Groningen
Glomerulonephritis, IGA, Hypertension
A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy
The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.
- Trial name
- NCT01184599
- Testing
- aliskiren
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Kagawa University
Chronic Kidney Disease, Proteinuria
Optimalization of Nephroprotection Using Atorvastatin (Sortis)
The main purpose of the study is find whether the addition of statin (Atorvastatin) to dual renin-angiotensin-aldosterone system blockade involving angiotensin converting enzyme inhibitor and AT-1 angiotensin II receptor blocker…
- Trial name
- NCT00572312
- Testing
- atorvastatin (Sortis) 40 mg
- Sponsor
- Medical University of Gdansk
Covid 19
Diagnosis of Endocrine Dysfunctions in Covid-19
As observed with SARS-CoV responsible for SARS 2003, the new coronarovirus SARS-CoV-2 uses the angiotensin converting enzyme type 2 (ACE2) as cellular receptor to infect cells.
- Trial name
- Dyhor-19 (NCT04587375)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Montpellier
Renin-Angiotensin Aldosterone System (RAS)
Human Intestinal Amino Acid Absorption and the Role of a Local RAS
This study is to find out what role a local intestinal RAS (renin angiotensin system) plays in the context of amino acid absorption in the human intestinal tract and how this RAS and thus the amino acid absorption is influenced…
- Trial name
- NCT04524494
- Testing
- biopsy of intestinal tissue, blood draw, urine collection
- Where
- 2 sites in Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital Basel
Hyperkalaemia, Heart Failure with Reduced Ejection Fraction
Hyperkalaemia and Its Impact on Therapy with RAASi
Renin-angiotensin-aldosterone system inhibitors (RAASi) have transformed prognosis of patients with heart failure with reduced ejection fraction, diabetic nephropathy and chronic kidney disease.
- Conditions
- Hyperkalaemia, Heart Failure with Reduced Ejection Fraction, Left Ventricular Systolic Dysfunction
- Trial name
- REVIEW (NCT04249648)
- Where
- United Kingdom
- Volunteers
- 651 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Kidney Failure, Chronic
Inhibition of Aldosterone in Patients With Chronic Renal Disease
The purpose of this study is to examine whether the inhibition of aldosterone will result in lower excretion of protein via urine.
- Trial name
- NCT00430924
- Testing
- Eplerenone
- Where
- 2 sites in Denmark
- Volunteers
- 42 people
- Sponsor
- Lene Boesby
Sepsis, Acute Kidney Injury Due to Sepsis
Renin Angiotensin Aldosterone System In Septic Kids
Prospective observational cohort study; pediatric sepsis vs. healthy pediatric subjects and pediatric sepsis with acute kidney injury (AKI) vs without AKI.
- Conditions
- Sepsis, Acute Kidney Injury Due to Sepsis, Acute Kidney Injury (Nontraumatic)
- Trial name
- RISK (NCT06295393)
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Obstructive Sleep Apnea
Vitamin D Levels and Heart Rate Variability on Endothelial Function Via RAAS Augmentation in OSA
The role of obstructive sleep apnea (OSA) in contributing to hyperaldosteronism, which can lead to increased morbidity and mortality, is less well-established.
- Trial name
- RAAS_OSA (NCT05232201)
- Where
- Malaysia
- Volunteers
- 150 people
- Sponsor
- University Malaysia Sarawak
COVID-19, SARS-CoV-2 Infection
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT04924660)
- Testing
- TXA127, TRV027, Fostamatinib
- Where
- 51 sites in United States
- Volunteers
- 1,060 people
- Sponsor
- Sean Collins
Heart Valve Diseases, Left Ventricle Remodeling
Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Undergoing Valve Surgery.
Why Is This Study Important? The heart has valves that help control blood flow. Aortic regurgitation (AR) is a condition where one of these valves (the aortic valve) doesn't close properly, causing blood to leak back into the…
- Conditions
- Heart Valve Diseases, Left Ventricle Remodeling, Aortic Regurgitation Disease, Heart Failure Congestive
- Trial name
- ARBNP (NCT07099859)
- Testing
- Losartan 50 mg
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Vitor Emer Egypto Rosa